Cited 0 times in
Update from the ongoing phase 1/2 registrational trial of repotrectinib: results in TKI-naïve and TKI-pretreated patients with NTRK fusion-positive advanced solid tumors (TRIDENT-1)
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.